WT1 and acute myeloid leukemia: More importantly, clinical efficacy following WT1-specific TCR-T-cell treatment was demonstrated by a relapse-free survival (RFS) of 100% at a median of 44 months, which was significantly higher than a comparable group of high-risk AML patients that did not receive TCR-T-cell therapy [55].